An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Faecal Incontinence: The Management of Faecal Incontinence in Adults.
London: National Collaborating Centre for Acute Care (UK); 2007. (NICE Clinical Guidelines, No. 49.)
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
Cardiff (UK): National Collaborating Centre for Cancer (UK); 2010 Jul. (NICE Clinical Guidelines, No. 104.)
Suspected neurological conditions: recognition and referral.
National Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2019 May. (NICE Guideline, No. 127.)
Vutrisiran (Amvuttra): CADTH Reimbursement Recommendation: Indication: For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin-mediated amyloidosis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.
Triheptanoin (Dojolvi): CADTH Reimbursement Recommendation: Indication: As a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.
Sacituzumab Govitecan (Trodelvy): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting [Internet].
WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update [Internet].
Geneva: World Health Organization; 2022.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Recommendation: Indication: Treatment of adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received at least one androgen receptor pathway inhibitor and taxane-based chemotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.
Enfortumab Vedotin (Padcev): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable, locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jan.
Pembrolizumab (Keytruda): CADTH Reimbursement Review: Therapeutic area: Triple-negative breast cancer [Internet].
Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence [Internet].
National Collaborating Centre for Primary Care (UK).
London: Royal College of General Practitioners (UK); 2009 Jan. (NICE Clinical Guidelines, No. 76.)
Selinexor (Xpovio): CADTH Reimbursement Recommendation: Indication: Multiple myeloma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Aug.
Sotorasib (Lumakras): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with Kirsten rat sarcoma viral oncogene homologue (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non–small cell lung cancer (NSCLC) who have received at least one prior systemic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Atezolizumab (Tecentriq): CADTH Reimbursement Recommendation: Indication: As monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with non–small cell lung cancer whose tumours have programmed death-ligand 1 expression on 50% or more of tumour cells [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.
Polatuzumab Vedotin (Polivy): CADTH Reimbursement Recommendation: Indication: Large B-cell lymphoma [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.
Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto): CADTH Reimbursement Review: Therapeutic area: Metastatic castration-resistant prostate cancer [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Bladder Cancer: Diagnosis and Management.
National Collaborating Centre for Cancer (UK).
London: National Institute for Health and Care Excellence (NICE); 2015 Feb. (NICE Guideline, No. 2.)
Non-Hodgkin's Lymphoma: Diagnosis and Management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)
Pancreatic cancer in adults: diagnosis and management.
London: National Institute for Health and Care Excellence (NICE); 2018 Feb. (NICE Guideline, No. 85.)
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on